Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 6:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alzheimer's Disease, Early Onset Clear all
Completed No phase listed Observational Accepts healthy volunteers

Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks

NCT03153371
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Disease, Late Onset, Dementia, Alzheimer Type, Logopenic Progressive Aphasia, Primary Progressive Aphasia, Visuospatial/Perceptual Abilities, Posterior Cortical Atrophy, Executive Dysfunction, Corticobasal Degeneration, Ideomotor Apraxia
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 5, 2026, 6:16 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

NCT05269394
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
E2814, Lecanemab, Matching Placebo (E2814)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 5, 2026, 6:16 PM EDT
Enrolling by invitation Not applicable Interventional

Cholinergic Deep Brain Stimulation for Alzheimer's Disease

NCT05882344
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Dementia, Alzheimer Disease
Interventions
Device Implantation- Boston Scientific, VERCISE GENUS™ system, DBS Stimulation - Boston Scientific, VERCISE GENUS™ system
Procedure · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 5, 2026, 6:16 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

NCT01760005
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, Matching Placebo (E2814)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
490 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 5, 2026, 6:16 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

ScentAware and OCT in MCI vs HC

NCT06377241
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
ScentAware, UPSIT
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 5, 2026, 6:16 PM EDT
Completed Not applicable Interventional

Ryan Companion Robot for Assisting Elderly People With Alzheimer's Disease

NCT05052866
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Social Robot
Behavioral
Lead sponsor
DreamFace Technologies, LLC
Industry
Eligibility
65 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 5, 2026, 6:16 PM EDT
Completed No phase listed Observational

A Practical Platform for In-Home Remote Monitoring of Cognitive Frailty

NCT05754021
View directory record Official record
Conditions
Frailty, Cognitive Impairment, Dementia, Cognitive Impairment, Mild, Alzheimer Disease, Alzheimer Disease, Early Onset
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
50 Years to 95 Years
Enrollment
100 participants
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 5, 2026, 6:16 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

NCT06424236
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Gantenerumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 5, 2026, 6:16 PM EDT
Recruiting Not applicable Interventional

Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

NCT02740634
View directory record Official record
Conditions
Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA), Alzheimer Disease, Alzheimer Disease, Early Onset, Amnestic Disorder, Amnestic Symptoms, Amnestic Mild Cognitive Disorder
Interventions
F-18 AV 1451, C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 5, 2026, 6:16 PM EDT
Completed Not applicable Interventional

A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)

NCT05637801
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
Interventions
Spectris™ AD - Active, Spectris™ AD - Sham
Device
Lead sponsor
Cognito Therapeutics, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
68
States / cities
Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 5, 2026, 6:16 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

NCT05552157
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Remternetug (SC), Matching Placebo (Remternetug)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
13
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 5, 2026, 6:16 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Reference Database & Longitudinal Registry of the Normal and Pathological Aging Brain

NCT02875496
View directory record Official record
Conditions
Early Onset Alzheimer Disease, Mild Cognitive Impairment, Depression, Aging
Interventions
Not listed
Lead sponsor
ElMindA Ltd
Industry
Eligibility
50 Years to 85 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
The Villages, Florida
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 5, 2026, 6:16 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

NCT05231785
View directory record Official record
Conditions
Early-Onset Alzheimer Disease
Interventions
ALN-APP, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
La Jolla, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 5, 2026, 6:16 PM EDT
Not yet recruiting Phase 1 Interventional

Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

NCT06600880
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid, MK-6240, Dotarem, Blood draw, UR5e, Urine test
Device · Drug · Other + 2 more
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 5, 2026, 6:16 PM EDT
Not listed No phase listed Observational

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

NCT06539169
View directory record Official record
Conditions
Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeld-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-Onset Alzheimer Disease, Ehlers-Danlos Syndrome, Huntington Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, Rare Diseases
Interventions
Not listed
Lead sponsor
xCures
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Altos, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 5, 2026, 6:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Studies in Familial Dementia

NCT04680013
View directory record Official record
Conditions
Dementia of Alzheimer Type, Alzheimer Disease, Late Onset, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Dementia
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
4,884 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 5, 2026, 6:16 PM EDT
Active, not recruiting Not applicable Interventional

Individualized Brain Stimulation to Improve Mobility in Alzheimer's Disease

NCT04289402
View directory record Official record
Conditions
Alzheimer Dementia, Presenile Alzheimer Dementia, Aging
Interventions
Personalized tDCS, Active-Sham
Other
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
65 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Roslindale, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 5, 2026, 6:16 PM EDT
Active, not recruiting No phase listed Observational

Illuminating Neuropsychological Dysfunction and Systemic Inflammatory Mechanisms Gleaned After Hospitalization in Trauma-ICU Study

NCT03098459
View directory record Official record
Conditions
Delirium, Cognitive Impairment, Alzheimer; Early Onset, Trauma, Polytrauma, Traumatic Brain Injury, ICU, Critical Illness
Interventions
Non-interventional observational prospective cohort study
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 5, 2026, 6:16 PM EDT
Completed Phase 1 Interventional

Efavirenz for Patients With Alzheimer's Disease

NCT03706885
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Sustiva Pill
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
55 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Beachwood, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 5, 2026, 6:16 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

NCT06268886
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
BMS-986446, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
50 Years to 80 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
119
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 5, 2026, 6:16 PM EDT
Completed No phase listed Observational

A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)

NCT04733989
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection
Other
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
16
States / cities
Aventura, Florida • Coral Gables, Florida • Lady Lake, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 5, 2026, 6:16 PM EDT
Active, not recruiting Phase 2 Interventional

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study

NCT04685590
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Interventions
Dasatinib + Quercetin, Placebo Capsules
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 5, 2026, 6:16 PM EDT
Not listed No phase listed Observational

Digital Evaluations and Technologies Enabling Clinical Translation for AD

NCT05385913
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Multivitamin-no intervention
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
65 Years and older
Enrollment
200 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 5, 2026, 6:16 PM EDT
Recruiting Not applicable Interventional

Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study

NCT05573490
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Cognitive Training, Tai Chi- Qi Gong, Brain Games, Stretching
Device · Behavioral
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 5, 2026, 6:16 PM EDT